Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers genetic testing services worldwide, today announced it has appointed Karl Odquist as executive director of managed care. Based at Pathway Genomics’ San Diego headquarters, Odquist will be responsible for managed care contracting, reimbursement, government affairs, and clinical evidence generation for the company’s diagnostic services.

“Karl’s knowledge and experience in coordinating managed care and business development efforts is extensive,” said Jim Plante, Pathway Genomics’ founder and CEO. “His background working with large-scale companies and payers will serve Pathway’s mission in expanding its genetic testing services to a wider network of physicians.”

Odquist has more than 20 years of experience working with payers in the pharmaceutical and medical benefit side of the health care field. Prior to joining Pathway Genomics, he served in various leadership roles for leading pharmaceutical and diagnostic companies, including Prometheus Laboratories, where he directed multiple internal and external high-performing field-based teams, helping the company to achieve more than $500 million in annual net revenue.


“Pathway Genomics has positioned itself as an industry leader with a mature perspective of the field,” said Odquist. “My goal is to maximize the reach of its line of testing services and make it accessible to more patients.”

“Pathway Genomics has positioned itself as an industry leader with a mature perspective of the field,” said Odquist. “My goal is to maximize the reach of its line of testing services and make it accessible to more patients.”

Comments are closed.